Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial
Achievement of primary efficacy endpoint in 3-arm SUI feasibility study demonstrates significant separation between CMRF treatment arm and inert sham arm
Positive in-vivo preclinical study validates new inert sham tip for use in upcoming pivotal PURSUIT Trial in U.S.
finance.yahoo.com/ne...icacy-100200629.html
Achievement of primary efficacy endpoint in 3-arm SUI feasibility study demonstrates significant separation between CMRF treatment arm and inert sham arm
Positive in-vivo preclinical study validates new inert sham tip for use in upcoming pivotal PURSUIT Trial in U.S.
finance.yahoo.com/ne...icacy-100200629.html